Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1

Status

Completed 47Recruiting 21Active not recruiting 21Unknown 11Withdrawn 8Terminated 7Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Liver Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Carboplatin 79Cisplatin 74Bevacizumab 62Radiotherapy 59Drug Therapy 57Capecitabine 57Oxaliplatin 56tislelizumab 54toripalimab 45Paclitaxel 44Gemcitabine 43pembrolizumab 40anlotinib 40Specimen Handling 39sintilimab 37Cyclophosphamide 34130-nm albumin-bound paclitaxel 34Injections 30Pemetrexed 28camrelizumab 26Surgical Procedures, Operative 26Magnetic Resonance Spectroscopy 25lenvatinib 24apatinib 23Docetaxel 23Etoposide 22S 1 (combination) 21Fluorouracil 21Immune Checkpoint Inhibitors 20Biopsy 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × tremelimumab × Clear all
NCT06855225 2026-04-17

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

Hoosier Cancer Research Network

Phase 2 Not yet recruiting
29 enrolled
Gastrointestinal

Liver Neoplasms

NCT07511504 2026-04-06

Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma

OHSU Knight Cancer Institute

Phase 2 Not yet recruiting
40 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡